Corvallis, MT, United States of America

Lonnie Bookbinder

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Lonnie Bookbinder: A Pioneer in Cancer Treatment Innovations

Introduction

Lonnie Bookbinder is an innovative inventor based in Corvallis, Montana, whose work focuses on developing groundbreaking treatments for cancer. With a strong commitment to advancing medical science, he has made a significant impact in the field of cancer research through his patented invention.

Latest Patents

Bookbinder holds a patent for "Reagents and methods for treating cancer." This invention presents a genetic approach for targeting the EVI1 gene in mammalian cells. The EVI1 gene serves as an oncogenic transcription factor that accelerates cell division and inhibits apoptosis. His patent describes nucleotide sequences designed to block EVI1 expression, effectively halting cell growth and division, and triggering cell death in various types of cancer, including lung and ovarian cancers.

Career Highlights

Lonnie Bookbinder's career has been marked by his dedication to innovation in cancer treatment. Working at Peptimed, Inc., he has contributed to cutting-edge research and development in pharmaceuticals. His work not only enhances therapeutic options for patients but also represents a hopeful stride in oncological advancements.

Collaborations

Throughout his career, Bookbinder has collaborated with skilled colleagues such as Thomas Primiano and Bey-Dih Chang. These partnerships have fostered a collaborative environment focused on tackling the complexities of cancer treatment through innovative scientific research.

Conclusion

Lonnie Bookbinder stands out as a vital contributor to the field of cancer research. His patented methods for targeting the EVI1 gene represent a significant leap forward in the fight against cancer, offering promising avenues for effective treatments. As he continues his work at Peptimed, Inc., the scientific community looks forward to the contributions that will arise from his innovative spirit and collaborative efforts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…